Clinical Trials
Many treatments for cancer today are the result of past clinical trials – research studies that involve patients. They are the final step in a long process that begins with lab research. Clinical trials study new ways to prevent, diagnose and treat cancer.
Having access to clinical trials at Central DuPage Hospital (CDH) allows patients throughout Chicago’s far western suburbs the opportunity to have new treatments, which may be more effective than current standard treatments.
Clinical trials may be an option in your cancer treatment, and with those studies being conducted right at CDH, you can be among the first to be considered for new treatments. Your doctor will discuss with you if there are clinical studies available that may be right for you, and for which you are eligible. If you are eligible, choosing to participate is your decision after your doctor has provided detailed information and has answered all your questions about the study.
Determining Your Eligibility
If you decide you would like to be considered for a clinical trial, your doctor and research nurse will give you a consent form to read and sign. The consent form will explain study criteria, steps in the study and any known side effects.
Trials Access for Children
Through an affiliation with the Children’s Oncology Group and other medical associations, CDH is involved in investigations that evaluate the effectiveness of new therapies.
Trials Access for Adults
CDH has been accepted as a component member of Southwest Oncology Group, and as an affiliate of the Gynecologic Oncology Group. These memberships allow CDH to offer adult patients access to a larger pool of clinical trials – and to contribute to improving cancer treatment for the future.
Clinical Trials at CDH
There are several clinical trials currently in progress at CDH. Talk with your physician to determine if you are eligible.
Breast Cancer
1. A Phase II Study of Carboplatin, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Avastin as the First-Line Therapy in Metastatic Breast Cancer
A study with a new combination of drugs for locally recurrent or advanced breast cancer patients
2. ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study- A Randomized, Multi-Center, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
A study of a drug therapy that may be effective in preventing the return or spread of cancer for women with early stage breast cancer and who have also had breast cancer surgery
3. A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab Plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer
A study that compares standard chemotherapy with a drug to help prevent the spread of cancer to the brain
4. NSABP Protocol B-39/TROG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
A study of treating early stage breast cancer with standard five-six weeks of radiation to the whole breast vs. localized radiation to the tumor site in the breast for five days at a higher dose of radiation
Colon Cancer
1. A Randomized, Double-Blind, Multicenter, Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients with Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy
A study which adds an additional new drug or placebo to standard chemotherapy in patients who have progressed during or following a first line treatment for metastatic colon cancer
Endometrial Cancer
1. A Phase III Open Label, Randomized, 2 Arm Study of Ixabeilone Administered Every 21 Days vs. Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy
A study that compares a new drug, Ixabepilone, with two standard chemotherapy drugs for women with advanced endometrial (uterine) cancer
2. A Phase III Trial of Pelvic Radiation Therapy vs. Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer
A study that compares standard radiation to the whole pelvis vs. local radiation treatment to the area of the tumor in women with endometrial (uterine) cancer at high risk for relapse
3. A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin & Paclitaxel vs. Carboplatin & Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma
A study for women who have had the majority of their endometrial (uterine) cancer removed with surgery that will evaluate the benefit of adding radiation therapy to the chemotherapy vs. chemotherapy alone
Ovarian Cancer
1. A Prospective, Longitudinal Study of YKL-40 in Patients with Figo Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy
A study using a new blood cancer marker to be used for early detection of ovarian cancer
2. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse (Morphotek)
A study that uses a new drug in combination with standard therapy in women with ovarian cancer that has persisted or worsened despite receiving platinum-based chemotherapy
3. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer
A study that uses a new drug in combination to prolong a second response in the platinum resistant or recurring patients
4. A Phase III Clinical Trial OF Bevacizumab With IV Versus IP Chemotherapy In Ovarian, Fallopian Tube, And Primary Peritoneal Carcinoma
A study that uses a new drug in combination with standard therapy for ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer
5. A Randomized Phase III Trial OF Cisplatin Plus Paclitaxel With And Without Bevacizumab Versus The Non-Platinum Doublet, Topotecan Plus Paclitaxel, With And Without NCI-Supplied Bevacizumab, In Stage IVB, Recurrent Or Persistent Carcinoma Of The Cervix
A study that uses a different combination of drugs along with a new drug for recurrent, or persistent cervical cancer
6. A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 vs. No Treatment Until Documented Relapse in Women with Advanced Ovarian Primary Peritoneal or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane based Chemotherapy
A study that looks at treating patients preventatively with a year of chemotherapy vs. no treatment in women with ovarian, peritoneal or fallopian tube cancer who have no evidence of disease after completing the initial chemotherapy
Lung Cancer
1. A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
A study with standard chemotherapy and possible new drug for high risk lung cancer
2. A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/ Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
A study that is uses a different combination of standard treatment plus a new drug for recurrent or advanced lung cancer
Leukemia
1. A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia
A study that evaluates adding two new drugs and two different schedules of standard chemotherapy and their effect on previously untreated Chronic Lymphocytic Leukemia (CLL)
Liposarcoma, Leiomyosarcoma
1. A Randomized Controlled Study of Yondelis (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with and Anthracycline and Ifosfamide
A study that compares a new drug vs. a standard drug in the treatment of advanced Liposarcoma or Leiomyosarcoma in patients previously treated with standard initial therapy
Lymphoma
1. A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging
A study that will have patients evaluated during treatment using a PET scan to determine if changes in chemotherapy are warranted
MDS
1. A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and In Combination with Epoetin Alfa (Procrit) in Subjects with Low-or Intermediate-1 risk MDS and Symptomatic Anemia
A study that compares giving patients either Revlimid or Revlimid and Procrit for their Myelodysplastic Syndrome (MDS) or symptomatic anemia to determine which is better in treating their disease
If you have questions about clinical trials in general, you can visit the following resources: